:en:MedImmune

{{Short description|Biopharmaceutical company, acquired by AstraZeneca in 2007}}

{{Infobox company

| name = MedImmune, LLC

| logo = MedImmune_logo.svg

| type = Subsidiary

| parent = AstraZeneca

| genre =

| fate =

| predecessor =

| successor =

| foundation = {{ubl

|{{start date and age|1988}} (as Molecular Vaccines, Inc.)

|{{start date and age|1989}} (as MedImmune, Inc.)

}}

| founder =

| defunct =

| location_city =

| location_country =

| location = Gaithersburg, Maryland, U.S.

| locations =

| area_served =

| key_people =

| industry = Pharmaceutical

| products = {{ubl

|Synagis

|FluMist

}}

| production =

| services =

| revenue =

| operating_income =

| net_income =

| aum =

| assets =

| equity =

| owner =

| num_employees =

| divisions =

| subsid =

| homepage = [https://web.archive.org/web/19961229200313/http://www.medimmune.com/ www.medimmune.com]

| footnotes =

| intl =

}}

MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.{{Cite web|url=http://www.evaluate.com/vantage/articles/news/corporate-strategy/12-years-astra-draws-line-under-medimmune|title=12 years on, Astra draws a line under Medimmune|date=2019-02-14|website=Evaluate.com|language=en|access-date=2019-02-15}}{{Cite web|url=https://www.biopharmadive.com/news/astrazeneca-retires-medimmune-name-amid-sales-turnaround/548489/|title=AstraZeneca retires Medimmune name amid sales turnaround|website=BioPharma Dive|language=en-US|access-date=2019-02-16}}

MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion.{{cite web|url=https://www.nytimes.com/2007/04/24/business/24drug-web.html|title=AstraZeneca Buys MedImmune for $15.6 Billion|first=Andrew|last=Pollack|work=The New York Times |date=24 April 2007|access-date=2 June 2019|via=NYTimes.com}} Its main offices were located in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA.{{Cite web |url=https://www.medimmune.com/about-us.html |title=About Us | MedImmune |access-date=2017-08-23 |archive-url=https://web.archive.org/web/20170830152939/https://www.medimmune.com/about-us.html |archive-date=2017-08-30 |url-status=dead }}

It produced Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune acquired FluMist when it purchased Aviron in 2002 for US$ 1.5 billion. FluMist sales totaled US$ 104 million in 2008, US$ 54.8 million in 2007, and US$ 36.4 million in 2006.{{cite news

| url=https://www.washingtonpost.com/wp-dyn/content/article/2009/06/01/AR2009060101608.html

| title=MedImmune Wins Key Contract To Develop Swine Flu Vaccine

| author=Michael S. Rosenwald

| date=June 2, 2009

| access-date=October 23, 2009

| newspaper=The Washington Post

}}

FluMist was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market—young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store.

• [http://www.medimmune.com Medimmune Company Site]
• [http://www.flumist.com Flumist nasal flu vaccine - Official website]
• Bishop, Tricia. "MedImmune loss in '05 quadruples shortfall from '04" Baltimore Sun. 3 February 2006.
• Rosenwald, Michael S. "[https://www.washingtonpost.com/wp-dyn/content/article/2006/02/02/AR2006020202320.html Sales of MedImmune's Flu Vaccine Drop Sharply]" Washington Post. 3 February 2006.

MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was approved by the U.S. Food and Drug Administration (FDA) in 2007, and is now the form offered on the market.